Neuroblastoma Drugs

Global Neuroblastoma Drugs Market to Reach US$1.1 Billion by 2030

The global market for Neuroblastoma Drugs estimated at US$849.1 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$616.8 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$225.4 Million While China is Forecast to Grow at 4.9% CAGR

The Neuroblastoma Drugs market in the U.S. is estimated at US$225.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$183.1 Million by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.8% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Neuroblastoma Drugs Market - Key Trends and Drivers Summarized

Neuroblastoma is a type of cancer that primarily affects young children and arises from immature nerve cells found in several areas of the body. The treatment landscape for neuroblastoma has evolved significantly over the years, with advancements in drug development playing a pivotal role in improving outcomes. Traditional treatment methods have included surgery, radiation therapy, and chemotherapy, but these approaches often come with significant side effects and varying degrees of success. Recently, there has been a shift towards more targeted therapies, which aim to directly interfere with the cancer cells` ability to grow and proliferate. One such targeted therapy is the use of monoclonal antibodies, like dinutuximab, which binds to the GD2 ganglioside found on neuroblastoma cells, thereby marking them for destruction by the immune system. Other notable drugs include ALK inhibitors, which target mutations in the ALK gene often found in neuroblastoma tumors, and retinoid therapy with drugs like isotretinoin, which induces cancer cell differentiation and death.

In addition to targeted therapies, immunotherapy has emerged as a promising avenue for treating neuroblastoma. This approach leverages the body`s immune system to fight cancer, with agents such as immune checkpoint inhibitors and CAR-T cell therapy showing encouraging results in clinical trials. Immune checkpoint inhibitors work by blocking proteins that prevent the immune system from attacking cancer cells, while CAR-T cell therapy involves genetically modifying a patient`s T-cells to recognize and kill cancer cells. These therapies are particularly valuable for patients with high-risk or relapsed neuroblastoma, who have limited options and typically poor prognoses. Moreover, recent advancements in genomics and personalized medicine are enabling more precise identification of the genetic alterations in neuroblastoma tumors, facilitating the development of drugs tailored to the specific molecular profiles of individual patients.

The growth in the neuroblastoma drugs market is driven by several factors, including the increasing incidence of neuroblastoma, heightened awareness and early diagnosis, and the expanding pipeline of innovative drugs. Advances in diagnostic technologies, such as next-generation sequencing and advanced imaging techniques, have significantly improved early detection rates, allowing for more timely and effective interventions. Furthermore, substantial investments in research and development by pharmaceutical companies and academic institutions are accelerating the discovery and approval of new therapies. The market is also benefiting from a growing emphasis on personalized medicine, which promises to enhance treatment efficacy and reduce adverse effects by tailoring therapies to the unique genetic makeup of each patient`s cancer. Additionally, regulatory agencies are increasingly offering incentives such as orphan drug designations and expedited review processes to encourage the development of treatments for rare diseases like neuroblastoma. Lastly, patient advocacy groups and non-profit organizations are playing a critical role in funding research and raising public awareness, further driving the demand for advanced neuroblastoma therapies.

SCOPE OF STUDY:

The report analyzes the Neuroblastoma Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Therapy (Immunotherapy, Chemotherapy, Other Therapies); Route of Administration (Injectables Administration, Oral Administration); Distribution Channel (Offline Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 86 Featured) -

• APEIRON Biologics AG
• Baxter International Inc.
• Bristol-Myers Squibb Company
• Cellectar Biosciences Inc.
• Clarity Pharmaceuticals
• Creative Biolabs
• Eli Lilly And Company
• Eugia US LLC
• Macrogenics Inc.
• Provectus Biopharmaceuticals, Inc.
• Recordati Group
• Sartorius AG
• United Therapeutics Corporation
• USWM, LLC.
• Y-mabs Therapeutics Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.